Aimmune Therapeutics (NASDAQ:AIMT) - a stellar bioscience firm that specializes in the delivery of medicine to manage food allergy - now presents itself as a bargain.

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials.

Aimmune is a highly promising bioscience company that seemingly has the answer to food allergy.
AR-101 passed its Phase 3 (PALISADE) trial for peanut allergy with flying colors.
Aimmune anticipates filing for a Biologic Licensing Application with the FDA in Q4 2018 and an approval is expected in Q2 2019.
AR-101 is highly likely to capture the $ Multi-Billion food allergy market that is currently without a dominant medicine.

( I own a very small stake and have held it for more than a year, but no other conflict of interst)

Unlock the rest of this Article in 15 seconds

or Unlock with your email

Already have an account?
Login here